Information Provided By:
Fly News Breaks for December 16, 2019
REGN, NTLA
Dec 16, 2019 | 14:14 EDT
After Intellia (NTLA) disclosed in a filing that its development partner Regeneron (REGN) will modify its share of worldwide development costs and profits NTLA-2001, an in vivo CRISPR-Cas9-based therapy to treat transthyretin amyloidosis, or ATTR, Roth Capital analyst Tony Butler noted that although Intellia is now entitled to 75% of profits arising from any worldwide sales of NTLA-2001, it will also incur added costs to develop NTLA-2001. He keeps a $16 price target and Neutral rating on Intellia shares following the news.
News For NTLA;REGN From the Last 2 Days
REGN
REGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.